EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

Akosua A Agyeman iD, Laura Buggiotti, Li-An K Brown, Jose A Guerra-Assuncao, Japhette E Kembou-Ringert, Wen Y Mak iD, Judith Breuer, David M Lowe, Joseph F Standing iD, FLARE Investigators

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70507 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Akosua A Agyeman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Infection, Immunity and Inflammation Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, Lond…. Hauptthemen laut MEDLINE: Pyrazines, Lopinavir, Ritonavir, Amides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LifeArc, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans. In this study, we report the secondary endpoints from the phase 2a randomized, double‐blind, 2 × 2 factorial placebo‐controlled FLARE trial, which studied the combination of favipiravir and lopinavir–ritonavir.

Methods

Population pharmacokinetic and viral dynamic models including data from 59 and 235 participants respectively were developed to assess the drug effect of favipiravir in combination with lopinavir–ritonavir. Viral whole‐genome sequencing was performed.

Results

The final joint model consisted of a slope–intercept exponential decay viral dynamic model and a one‐compartment model with first‐order absorption and elimination for favipiravir pharmacokinetics. The mean death rate of infected cells ( δ ) was 0.96 day −1 . Favipiravir mean apparent clearance ( CL / F ) and mean apparent volume of distribution were 1.73 L/h and 22.1 L, respectively. Favipiravir co‐administration with lopinavir–ritonavir increased CL / F by twofold, representing an unexpected drug–drug interaction. Favipiravir and lopinavir–ritonavir drug effects on δ did not improve model fit in the final joint model, indicating that neither drug has any antiviral effect against SARS‐CoV‐2. Viral sequencing did not show a clear mutagenic signature.

Conclusions

Our findings suggest that favipiravir does not have antiviral activity at the dose used in our study, and further work to understand the mechanistic basis of the drug–drug interaction with lopinavir–ritonavir is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazinesLopinavirRitonavirAmidesAntiviral AgentsCOVID-19 Drug TreatmentHumansDrug CombinationsMaleDrug Therapy, CombinationSARS-CoV-2FemaleAdultDouble-Blind MethodMiddle AgedModels, BiologicalCOVID-19Drug Interactions

Stichwörter der Autor:innen

COVID‐19favipiravirlopinavir–ritonavirpopulation pharmacokinetic/pharmacodynamic modellingviral whole‐genome sequence

Substanzen

PyrazinesLopinavirfavipiravirRitonavirAmidesAntiviral AgentsDrug Combinationslopinavir-ritonavir drug combination

Autor:innen und Institutionen

  • Infection, Immunity and Inflammation Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London, UK.
  • Institute of Immunity and Transplantation, University College London, Royal Free Campus, London, UK.
  • Clinical Research Centre, Penang General Hospital, George Town, Penang, Malaysia.
  • Institute for Clinical Research, National Institutes of Health, Shah Alam, Selangor, Malaysia.
  • Department of Microbiology, Great Ormond Street Hospital for Children, London, UK.
  • Department of Clinical Immunology, Royal Free London NHS Foundation Trust, London, UK.

ORCID-Profile: Akosua A Agyeman, Wen Y Mak, Joseph F Standing

Förderung

  • LifeArc
  • Medical Research Council

Zitieren

APA

Agyeman, A. A., Buggiotti, L., Brown, L. K., Guerra-Assuncao, J. A., Kembou-Ringert, J. E., Mak, W. Y., Breuer, J., Lowe, D. M., Standing, J. F., & FLARE Investigators (2026). Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70507

Vancouver

Agyeman AA, Buggiotti L, Brown LK, Guerra-Assuncao JA, Kembou-Ringert JE, Mak WY, et al. Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70507

BibTeX
@article{Agyeman2026,
  author = {Agyeman, Akosua A and Buggiotti, Laura and Brown, Li-An K and Guerra-Assuncao, Jose A and Kembou-Ringert, Japhette E and Mak, Wen Y and Breuer, Judith and Lowe, David M and Standing, Joseph F and FLARE Investigators, FLARE Investigators},
  title = {Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70507}
}
Kostenlos starten →